{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:40:08Z","timestamp":1740166808286,"version":"3.37.3"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"Supplement_5","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,21]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Hepatitis C virus (HCV) testing is recommended for all adults 18 years and older to increase identification of those with infection and facilitate prompt referral for curative antiviral therapy. While critical to promote elimination, this strategy excludes a key demographic group who are clearly at risk of undetected HCV infection and who could benefit from early treatment: adolescents. In this paper, we review the available data on the burden of HCV and the close association with injection drug use, discuss the rationale of universal testing in adolescents and, finally, present data from a quality improvement project implementing HCV testing into routine adolescent health visits.<\/jats:p>","DOI":"10.1093\/jpids\/piae107","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T15:49:43Z","timestamp":1729093783000},"page":"S166-S170","source":"Crossref","is-referenced-by-count":0,"title":["Integrating Universal Hepatitis C Screening Into Adolescent Well Visits Is a \u201cWin-Win\u201d Scenario: Rationale and Demonstration of Real-world Feasibility and Implementation"],"prefix":"10.1093","volume":"13","author":[{"given":"Caren","family":"Mangarelli","sequence":"first","affiliation":[{"name":"Division of Advanced General Pediatrics, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preethi","family":"Raghupatruni","sequence":"additional","affiliation":[{"name":"Division of Advanced General Pediatrics, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomitra","family":"Latimer","sequence":"additional","affiliation":[{"name":"Division of Advanced General Pediatrics, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago , Chicago, Illinois ,","place":["USA"]},{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9921-0419","authenticated-orcid":false,"given":"Ravi","family":"Jhaveri","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Northwestern University Feinberg School of Medicine , Chicago, Illinois ,","place":["USA"]},{"name":"Division of Infectious Diseases, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago , Chicago, Illinois ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"2024112117453509600_CIT0001","doi-asserted-by":"crossref","first-page":"399","DOI":"10.15585\/mmwr.mm6914a2","article-title":"Vital signs: newly reported acute and chronic Hepatitis C cases - United States, 2009-2018","volume":"69","author":"Ryerson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024112117453509600_CIT0002","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1093\/cid\/ciu643","article-title":"Emerging epidemic of Hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012","volume":"59","author":"Suryaprasad","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2024112117453509600_CIT0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6902a1","article-title":"CDC recommendations for Hepatitis C screening among adults - United States, 2020","volume":"69","author":"Schillie","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2024112117453509600_CIT0004","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jama.2020.1123","article-title":"Screening for Hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement","volume":"323","author":"Owens","year":"2020","journal-title":"JAMA"},{"key":"2024112117453509600_CIT0005","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1053\/j.gastro.2018.02.035","article-title":"Individual state Hepatitis C data supports expanding screening beyond baby boomers to all adults","volume":"154","author":"Morse","year":"2018","journal-title":"Gastroenterology"},{"key":"2024112117453509600_CIT0006","doi-asserted-by":"crossref","first-page":"e2020049776","DOI":"10.1542\/peds.2020-049776","article-title":"2021 recommendations for preventive pediatric health care","volume":"147","author":"Committee on Practice and Ambulatory Medicine; Bright Futures Periodicity Schedule Workgroup","year":"2021","journal-title":"Pediatrics"},{"volume-title":"Viral hepatitis national strategic plan for the United States: a roadmap to elimination (2021\u20132025)","year":"2020","author":"US Department of Health and Human Services","key":"2024112117453509600_CIT0007"},{"key":"2024112117453509600_CIT0008","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpeds.2017.09.016","article-title":"Increasing prevalence of Hepatitis C among hospitalized children is associated with an increase in substance abuse","volume":"192","author":"Barritt","year":"2018","journal-title":"J Pediatr"},{"author":"Indiana State Department of Health","key":"2024112117453509600_CIT0009"},{"year":"2021","author":"Connecticute Department of Public Health","key":"2024112117453509600_CIT0010"},{"year":"2015","author":"Oregon Health Authority Public Health Department, Acute and Communicable Disease Program","key":"2024112117453509600_CIT0011"},{"key":"2024112117453509600_CIT0012","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1001\/jama.2021.6700","article-title":"The pandemic stay-at-home order and opioid-involved overdose fatalities","volume":"325","author":"Mason","year":"2021","journal-title":"JAMA"},{"key":"2024112117453509600_CIT0013","doi-asserted-by":"crossref","first-page":"362","DOI":"10.15585\/mmwr.mm7010a3","article-title":"Notes from the field: opioid overdose deaths before, during, and after an 11-Week COVID-19 stay-at-home order - Cook County, Illinois, January 1, 2018\u2013October 6, 2020","volume":"70","author":"Mason","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024112117453509600_CIT0014","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013\u20132019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"author":"Centers for Disease Control and Prevention","key":"2024112117453509600_CIT0015"},{"key":"2024112117453509600_CIT0016","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jpids\/piz065","article-title":"Hepatitis C virus screening among adolescents attending a drug rehabilitation center","volume":"9","author":"Fernandes","year":"2020","journal-title":"J. Pediatric Infect Dis Soc"},{"key":"2024112117453509600_CIT0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/cid\/cix798","article-title":"Cost-effectiveness of one-time Hepatitis C screening strategies among adolescents and young adults in primary care settings","volume":"66","author":"Assoumou","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2024112117453509600_CIT0018","doi-asserted-by":"crossref","first-page":"e20193060","DOI":"10.1542\/peds.2019-3060","article-title":"We need a new national strategy for Hepatitis C virus screening","volume":"145","author":"Jhaveri","year":"2020","journal-title":"Pediatrics"},{"key":"2024112117453509600_CIT0019","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.30830","article-title":"Ledipasvir-sofosbuvir for 12 weeks in children 3 to &lt;6 years old with chronic Hepatitis C","volume":"71","author":"Schwarz","year":"2020","journal-title":"Hepatology"},{"key":"2024112117453509600_CIT0020","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic Hepatitis C virus: part 1 of the DORA study","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"volume-title":"Safety and efficacy of sofosbuvir\/velpatasvir in pediatric patients 6 to &lt; 18 years old with chronic Hepatitis C infection","year":"2019","author":"Jonas","key":"2024112117453509600_CIT0021"},{"key":"2024112117453509600_CIT0022","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/hep.31841","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic HCV: part 2 of the DORA study","volume":"74","author":"Jonas","year":"2021","journal-title":"Hepatology"},{"key":"2024112117453509600_CIT0023","doi-asserted-by":"crossref","first-page":"S213","DOI":"10.1542\/peds.2009-2107C","article-title":"Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report","volume":"128","author":"Expert Panel on Integrated Guidelines for Cardiovascular H, Risk Reduction in C, Adolescents, National Heart L, Blood I","year":"2011","journal-title":"Pediatrics"},{"key":"2024112117453509600_CIT0024","first-page":"1","article-title":"Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings","volume":"55","author":"Branson","year":"2006","journal-title":"MMWR Recomm Rep"},{"key":"2024112117453509600_CIT0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.15585\/mmwr.su6901a2","article-title":"Condom and contraceptive use among sexually active high school students - youth risk behavior survey, United States, 2019","volume":"69","author":"Szucs","year":"2020","journal-title":"MMWR Suppl"},{"key":"2024112117453509600_CIT0026","doi-asserted-by":"crossref","first-page":"267","DOI":"10.15585\/mmwr.mm6811e1","article-title":"Vital signs: HIV transmission along the continuum of care - United States, 2016","volume":"68","author":"Li","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024112117453509600_CIT0027","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1001\/jama.2019.6587","article-title":"Screening for HIV infection: US Preventive Services Task Force Recommendation Statement","volume":"321","author":"Force","year":"2019","journal-title":"JAMA"},{"key":"2024112117453509600_CIT0028","doi-asserted-by":"crossref","first-page":"e2021055207","DOI":"10.1542\/peds.2021-055207","article-title":"Adolescents and young adults: the pediatrician\u2019s role in HIV testing and pre- and postexposure HIV prophylaxis","volume":"149","author":"Hsu","year":"2022","journal-title":"Pediatrics"},{"year":"2019","author":"Centers for Disease Control and Prevention","key":"2024112117453509600_CIT0029"},{"year":"2021","author":"Centers for Disease Control and Prevention","key":"2024112117453509600_CIT0030"},{"key":"2024112117453509600_CIT0031","doi-asserted-by":"crossref","first-page":"e20183610","DOI":"10.1542\/peds.2018-2587","article-title":"Supporting the health care transition from adolescence to adulthood in the medical home","volume":"142","author":"White","year":"2018","journal-title":"Pediatrics"},{"volume-title":"Epclusa (sofosbuvir\/velpatasvir) product label","year":"2020","author":"Gilead Sciences Inc","key":"2024112117453509600_CIT0032"},{"volume-title":"Mavyret (glecaprevir\/pibrentasvir) product label","year":"2020","author":"Abbvie Inc","key":"2024112117453509600_CIT0033"},{"year":"2024","key":"2024112117453509600_CIT0034"}],"container-title":["Journal of the Pediatric Infectious Diseases Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpids\/advance-article-pdf\/doi\/10.1093\/jpids\/piae107\/59811493\/piae107.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/Supplement_5\/S166\/60780835\/piae107.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpids\/article-pdf\/13\/Supplement_5\/S166\/60780835\/piae107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T17:45:51Z","timestamp":1732211151000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpids\/article\/13\/Supplement_5\/S166\/7824123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":34,"journal-issue":{"issue":"Supplement_5","published-online":{"date-parts":[[2024,10,16]]},"published-print":{"date-parts":[[2024,11,21]]}},"URL":"https:\/\/doi.org\/10.1093\/jpids\/piae107","relation":{},"ISSN":["2048-7207"],"issn-type":[{"type":"electronic","value":"2048-7207"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,10,16]]}}}